Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Learning from the best: seven steps to exceptional launches

Repurposing ‘YOLO’ to stand for ‘You Only Launch Once’

Top 10 benefits of virtual advisory boards: Increased Engagement and Insights

#2. Increased Advisor Engagement and Quality and Quantity of Insights

Impetus Digital

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

International study reveals 11 new genes linked to aggressive prostate cancer

Findings from the study could improve treatment options for patients with prostate cancer

- PMLiVE

New vaccine technology could help fight future viruses and variants

The antigen technology could enhance vaccine protection against potential threats

- PMLiVE

The five ‘innovation areas’ driving success in chronic diseases

How to gauge implementation complexity in order to unlock the full value of innovative products

- PMLiVE

Being healthy

Insights from this year’s annual Edelman Trust Barometer health data

The Power of Visuals

The Power of Visuals.

Emotion is the core of healthcare storytelling, but there are many ways to do it. This week, Jon from our Design Team explores a few mediums for doing so, from...

The Good Ideas Group

- PMLiVE

Disseminating Outcomes and Impact in Berlin

The Medscape Education Global team is looking forward to a busy time in Berlin at the EADV Congress 2023. During the congress, Medscape will be presenting five posters examining the...

Medscape Education

- PMLiVE

Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

About ten million people worldwide are affected by inflammatory bowel disease

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links